ReviewCurrent treatment options in allergy2014
Epicutaneous Immunotherapy for Aeroallergen and Food Allergy.
Review in Current treatment options in allergy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Food allergy: begin at the skin, end at the mast cell?Nature reviews. Immunology · 2025Review
- Application of PLGA-PEG-PLGA Nanoparticles to Percutaneous Immunotherapy for Food Allergy.Molecules (Basel, Switzerland) · 2024Article
- An epicutaneous therapeutic pollen-allergen extract delivery system in an allergic rhinitis mouse model: based on allergen loading on DC-specific aptamers conjugated nanogolds.Immunologic research · 2024Article
- Clinical and experimental treatment of allergic asthma with an emphasis on allergen immunotherapy and its mechanisms.Clinical and experimental immunology · 2023Article
- Recent advances in epicutaneous immunotherapy and potential applications in food allergy.Frontiers in allergy · 2023Review
- The Role of Regulatory T Cells in Epicutaneous Immunotherapy for Food Allergy.Frontiers in immunology · 2021Review
- Regional Differences in Food Allergies.Clinical reviews in allergy & immunology · 2019Review
- Review
- Assessment of Th1/Th2 Bias of STING Agonists Coated on Microneedles for Possible Use in Skin Allergen Immunotherapy.Molecular pharmaceutics · 2018Article
- Skin as an immune organ and clinical applications of skin-based immunotherapy.The World Allergy Organization journal · 2018Review
- Next generation immunotherapy for tree pollen allergies.Human vaccines & immunotherapeutics · 2017Review
- [Innovative forms of specific immunotherapy].Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete · 2017Review
- Article
- Therapeutic vaccines for allergic disease.NPJ vaccines · 2017Article
- Laser-facilitated epicutaneous immunotherapy to IgE-mediated allergy.Journal of controlled release : official journal of the Controlled Release Society · 2016Article
- Improving the safety of oral immunotherapy for food allergy.Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology · 2016Review
- Superior Suppressive Capacity of Skin Tregs Compared with Lung Tregs in a Model of Epicutaneous Priming.The Journal of investigative dermatology · 2015Article
- Recent advances in immunotherapy and vaccine development for peanut allergy.Therapeutic advances in vaccines · 2015Review
- Modified allergens and their potential to treat allergic disease.Current allergy and asthma reports · 2014Review
- Peanut immunotherapy.Clinical and translational allergy · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgE-mediated allergies today affect up to 30 % of the population in industrialized countries. Allergen immunotherapy is the only disease-modifying treatment option with a long-term effect. However, very few patients (<5 %) choose immunotherapy, due to the long treatment duration (between 3-5 years) and possible local and systemic allergic side effects of the allergen administrations. The latter occur when an allergen accidentally reaches the blood circulation. Therefore, the ideal application route for allergen immunotherapy should be characterized by two hallmarks: firstly, by a high number of potent antigen-presenting cells, which enhance efficacy and thus shorten treatment duration. Secondly, the allergen administration site is ideally non-vascularized, so that inadvertent systemic distribution of the allergen and consequent systemic allergic side effects are minimized. The epidermis contains high numbers of potent antigen-presenting Langerhans cells and, as an epithelium, is non-vascularized. Therefore, the epidermis represents an interesting administration route. Historical evidence for the clinical efficacy of epicutaneous allergy immunotherapy (EPIT) has now been strengthened by a number of recent double-blinded placebo-controlled clinical trials performed by independent groups. We review the immunological rationale, history and clinical experience with epicutaneous allergy immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.